WP1122 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a glucose analog that disrupts cellular energy metabolism, particularly in cancer cells, which often rely heavily on glycolysis for energy production. By inhibiting glycolysis, WP1122 can induce metabolic stress in cancer cells, leading to reduced proliferation and increased cell death. This mechanism makes it a promising candidate for targeting aggressive and treatment-resistant cancers, such as glioblastoma. Additionally, its ability to sensitize cancer cells to other treatments, like chemotherapy and radiation, enhances its utility in combination therapies. Research is ongoing to explore its efficacy in preclinical and clinical settings, particularly in cancers with limited treatment options.